

wherein R^1, R^2, and R^3 independently are selected from the group consisting of H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_6 cycloalkyl, substituted C_3-C_6 cycloalkyl, heterocycloalkyl, C_6-C_{12} aryl, C_6-C_{12} substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group, provided that at least one of R^1, R^2, or R^3 is H,

R^5, R^7, R^8, R^9 and R^{10} independently are selected from the group consisting of H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_6-C_{12} aryl, and substituted C_6-C_{12} aryl, and R^8 and R^9 together or R^7 and R^9 together may form a cycloalkyl or substituted cycloalkyl ring,

R^4 and R^6 together form a direct bond or are independently selected from the group consisting of C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_6-C_{12} aryl, and substituted C_6-C_{12} aryl, and wherein NR^{10} is located at the N-terminus of said peptide, or is located on an amino acid side chain of said peptide;

REMARKS

I. INTRODUCTION

Claim 24 has been amended. Entry of the foregoing amendments to claim 24 is respectfully requested. Upon entry of this amendment, claims 24 - 43 will be pending in this application.

II. THE OFFICE ACTION

A. Rejections based on 35 U.S.C. § 112, First Paragraph-Written Description

Claims 24 - 40 and 42 - 43 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking written description. Applicants respectfully traverse this ground for rejection.